Adjuvant therapy for colon carcinoma

Current status and future directions

Frank A Sinicrope, S. M. Sugarman

Research output: Contribution to journalArticle

Abstract

THE ADDITION of levamisole to 5-fluorouracil (5-FU) has been shown to improve overall survival in patients with resected lymph node-positive colon carcinoma, establishing this regimen as standard adjuvant therapy. Given that biochemical modulation of 5-FU by leucovorin has been shown to increase response rates in advanced disease, ongoing studies aim to evaluate this combination in the adjuvant setting. The possibility that levamisole and leucovorin may have additive effects is also under investigation. Further improvements in survival rates may be achieved through use of tumor vaccines, interferon-alpha, and new chemotherapeutic agents. Current efforts are also aimed at reducing the toxic effects of cancer chemotherapy. Advances in tumor biology may reveal new prognostic markers that may ultimately lead to more selective use of adjuvant cytotoxic therapy.

Original languageEnglish (US)
Pages (from-to)344-351
Number of pages8
JournalCancer Bulletin
Volume46
Issue number4
StatePublished - 1994

Fingerprint

Levamisole
Leucovorin
Fluorouracil
Colon
Carcinoma
Cancer Vaccines
Poisons
Interferon-alpha
Neoplasms
Survival Rate
Lymph Nodes
Drug Therapy
Survival
Therapeutics
Direction compound

ASJC Scopus subject areas

  • Cancer Research

Cite this

Adjuvant therapy for colon carcinoma : Current status and future directions. / Sinicrope, Frank A; Sugarman, S. M.

In: Cancer Bulletin, Vol. 46, No. 4, 1994, p. 344-351.

Research output: Contribution to journalArticle

@article{52caf46b9c624fe4aa03d60567b260a5,
title = "Adjuvant therapy for colon carcinoma: Current status and future directions",
abstract = "THE ADDITION of levamisole to 5-fluorouracil (5-FU) has been shown to improve overall survival in patients with resected lymph node-positive colon carcinoma, establishing this regimen as standard adjuvant therapy. Given that biochemical modulation of 5-FU by leucovorin has been shown to increase response rates in advanced disease, ongoing studies aim to evaluate this combination in the adjuvant setting. The possibility that levamisole and leucovorin may have additive effects is also under investigation. Further improvements in survival rates may be achieved through use of tumor vaccines, interferon-alpha, and new chemotherapeutic agents. Current efforts are also aimed at reducing the toxic effects of cancer chemotherapy. Advances in tumor biology may reveal new prognostic markers that may ultimately lead to more selective use of adjuvant cytotoxic therapy.",
author = "Sinicrope, {Frank A} and Sugarman, {S. M.}",
year = "1994",
language = "English (US)",
volume = "46",
pages = "344--351",
journal = "Cancer Bulletin",
issn = "0008-5448",
publisher = "Medical Arts Publishing",
number = "4",

}

TY - JOUR

T1 - Adjuvant therapy for colon carcinoma

T2 - Current status and future directions

AU - Sinicrope, Frank A

AU - Sugarman, S. M.

PY - 1994

Y1 - 1994

N2 - THE ADDITION of levamisole to 5-fluorouracil (5-FU) has been shown to improve overall survival in patients with resected lymph node-positive colon carcinoma, establishing this regimen as standard adjuvant therapy. Given that biochemical modulation of 5-FU by leucovorin has been shown to increase response rates in advanced disease, ongoing studies aim to evaluate this combination in the adjuvant setting. The possibility that levamisole and leucovorin may have additive effects is also under investigation. Further improvements in survival rates may be achieved through use of tumor vaccines, interferon-alpha, and new chemotherapeutic agents. Current efforts are also aimed at reducing the toxic effects of cancer chemotherapy. Advances in tumor biology may reveal new prognostic markers that may ultimately lead to more selective use of adjuvant cytotoxic therapy.

AB - THE ADDITION of levamisole to 5-fluorouracil (5-FU) has been shown to improve overall survival in patients with resected lymph node-positive colon carcinoma, establishing this regimen as standard adjuvant therapy. Given that biochemical modulation of 5-FU by leucovorin has been shown to increase response rates in advanced disease, ongoing studies aim to evaluate this combination in the adjuvant setting. The possibility that levamisole and leucovorin may have additive effects is also under investigation. Further improvements in survival rates may be achieved through use of tumor vaccines, interferon-alpha, and new chemotherapeutic agents. Current efforts are also aimed at reducing the toxic effects of cancer chemotherapy. Advances in tumor biology may reveal new prognostic markers that may ultimately lead to more selective use of adjuvant cytotoxic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028048450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028048450&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 344

EP - 351

JO - Cancer Bulletin

JF - Cancer Bulletin

SN - 0008-5448

IS - 4

ER -